KPH2f is a novel, orally bioactive and potent dual URAT1/GLUT9 inhibitor with the potential to be used an anti-hyperuricemic agent for gout treatment.

Verinurad (formerly known as RDEA-3170; RDEA3170) is a novel, highly potent and specific URAT1 (Urate transporter 1) inhibitor with anti-hyperuricemic effects.

Lesinurad (formerly RDEA-594; RDEA594; trade name: Zurampic) is a potent and selective URAT1 (urate transporter 1) inhibitor approved as an anti-gout medication in 2016 by FDA.

Lesinurad sodium (formerly known as RDEA594; RDEA-594; trade name Zurampic), the sodium salt of lesinurad, is a selective inhibitor of URAT1 (urate transporter 1) and OAT (organic anion transporter) approved in 2015 for treating high blood uric acid levels associated with gout.